
The Hydration Pharmaceuticals Company Limited

ACN 620 385 677

PROSPECTUS

Non-renounceable pro-rata entitlement offer of 2 New Shares for every 3 Shares held on the Record Date at an issue price of \$0.004 per New Share, together with 1 free-attaching New Option for every 2 New Shares subscribed for and issued, with an exercise price of \$0.006 each, expiring 30 June 2029.

To raise gross proceeds of up to \$1,434,635 (before costs).

The Company is also conducting a Share Sale Facility for holders of an Unmarketable Parcel of Shares in conjunction with the Offer.

IMPORTANT INFORMATION

This is an important document which should be read in its entirety before making any investment decision. If you are in any doubt as to the contents of this Prospectus, you should consult your stockbroker, lawyer, accountant or other professional adviser without delay. The Shares offered by this Prospectus should be considered speculative.

Important Notices

1.1 Transaction specific prospectus

This Prospectus is issued by The Hydration Pharmaceuticals Company Limited ACN 620 385 677 (**Company** or **HPC**) for the purpose of Chapter 6D of the *Corporations Act 2001* (Cth) (**Corporations Act**).

This Prospectus is a transaction-specific prospectus issued in accordance with section 713 of the Corporations Act and relates to continuously quoted securities within the meaning of that section. It does not contain the same level of disclosure as an initial public offering prospectus and is only required to contain information in relation to the effect of the issue of securities on a company and the rights attaching to the securities. It is not necessary to include general information in relation to all of the assets and liabilities, financial position, profits and losses or prospects of the issuing company.

Representations contained in this Prospectus are made taking into account that the Company is a disclosing entity for the purposes of the Corporations Act and certain matters are publicly available information or may reasonably be expected to be known to investors and professional advisers whom prospective investors may consult.

1.2 Lodgement and listing

This prospectus is dated 23 October 2026 and was lodged with the Australian Securities and Investments Commission (**ASIC**) on that date.

Neither ASIC, ASX Limited (**ASX**) nor any of their respective officers take any responsibility for the contents of this Prospectus or the merits of the investment to which this Prospectus relates.

The Company will apply to ASX within 7 days after the date of this Prospectus for official quotation of the New Shares offered pursuant to this Prospectus.

The Company also intends to apply to ASX for official quotation of the New Options. Quotation of the New Options is subject to ASX's quotation requirements being satisfied (as further described in Sections 2.5 and 5.2(g)) and there is no guarantee that quotation of the New Options will be granted. If quotation of the New Options is not granted, the New Options will be issued as unlisted securities and will not be tradeable on ASX. Nothing in this Prospectus is to be construed as stating or implying that the New Options will be quoted (listed) at any particular time, or at all. The fact that ASX may grant official quotation of any of the Securities is not to be taken in any way as an indication of the merits of the Company or those Securities.

No New Shares, New Options or Broker Options will be issued pursuant to this Prospectus later than 13 months after the date of this Prospectus.

1.3 Note to applicants

The Offer contained in this Prospectus is an invitation to apply for New Shares and New Options in the Company. This Prospectus contains important information about the Offer and the Company. You should read this Prospectus in its entirety before deciding whether to apply for New Shares and New Options. In particular, you should carefully consider the risk factors set out in Section 6 of this Prospectus and consider those risks in light of your personal financial situation, investment objectives and particular needs.

The New Shares and New Options offered under this Prospectus should be considered speculative. An investment in the Company involves a high degree of risk and is suitable only for investors who can stand the loss of some or all of their investment.

1.4 Overseas shareholders

This Prospectus does not constitute an offer or invitation in any place in which, or to any person to whom, it would not be lawful to make such an offer or invitation. No action has been taken to register or qualify the Shares or the Offer in any jurisdiction outside Australia or New Zealand. The distribution of this Prospectus (including in electronic form) outside Australia or New Zealand may be restricted by law and persons who come into possession of this Prospectus outside Australia or New Zealand should seek advice on and observe any such restrictions. Any failure to comply with such restrictions may constitute a violation of applicable securities laws.

It is not practicable for the Company to comply with the securities laws of overseas jurisdictions having regard to the number of overseas Shareholders, the number and value of New Shares these Shareholders would be offered and the cost of complying with regulatory requirements in each relevant jurisdiction. Accordingly, the Offer is not being extended and securities will not be issued to Shareholders with a registered address which is outside Australia or New Zealand.

For further information on overseas Shareholders please refer to Section 2.9.

1.5 Do not rely on forward-looking statements

This Prospectus contains forward-looking statements which are identified by words such as “believes”, “estimates”, “expects”, “intends”, “may”, “will”, “would”, “could” or “should” and other similar words that involve risks and uncertainties. These statements are based on an assessment of present economic and operating conditions, and on a number of assumptions regarding future events and actions that, as at the date of this Prospectus, are expected to take place.

Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of the Company. The Company cannot and does not give assurances that the results, performance or achievements expressed or implied in the forward-looking statements contained in this Prospectus will actually occur and investors are cautioned not to place undue reliance on these forward-looking statements.

Forward-looking statements should be read in conjunction with the risks set out in Section 6 (*Risk Factors*) and other information in this Prospectus. These and other factors could cause actual results to differ materially from those expressed in any forward-looking statements.

1.6 Continuous disclosure obligations

The Company is a “disclosing entity” (as defined in section 111AC of the Corporations Act) and is subject to regular reporting and disclosure obligations, including a requirement to continuously disclose any information it has to the market which a reasonable person would expect to have a material effect on the price or the value of the Shares.

The Company releases any information which it reasonably considers to be ‘price sensitive information’ publicly through ASX before it is disclosed to Shareholders and other market participants.

The Company manages the distribution of other information to Shareholders and other market participants through disclosure to the ASX and posts this information on its website www.hydralyte.com/pages/investors after the ASX confirms an announcement has been made.

This Prospectus is intended to be read in conjunction with the publicly available information in relation to the Company which has been notified to ASX and does not include all of the information that would be included in a prospectus for an initial public offering of securities in an entity that is not already listed on a stock exchange. Investors should therefore have regard to the other publicly available information in relation to the Company before making a decision whether or not to invest.

Having taken such precautions and having made such enquires as are reasonable, the Company believes that it has complied with the general and specific requirements of ASX as applicable from time to time throughout the three months before the issue of this Prospectus which required the Company to notify ASX of information about specified events or matters as they arise for the purpose of ASX making that information available to the stock market conducted by ASX.

Please refer to section 7.1 for further details.

1.7 Target market determination

In accordance with the design and distribution obligations under the Corporations Act, the Company has determined the target market for the offer of New Options under this Prospectus. The target market determination (TMD) is available on the Company's website at www.hydralyte.com/pages/investors. By making an Application under the Offer, you warrant that you have read and understood the TMD and that you fall within the target market set out in the TMD.

1.8 No investment advice

The information contained in this Prospectus is not financial product advice or investment advice and does not take into account your financial or investment objectives, financial situation or particular needs (including financial or taxation issues). You should seek professional advice from your accountant, financial adviser, stockbroker, lawyer or other professional adviser before deciding to subscribe for Securities under this Prospectus to determine whether it meets your objectives, financial situation and needs.

1.9 Electronic prospectus

A copy of this Prospectus can be downloaded from the website of the Company at www.hydralyte.com/pages/investors. If you are accessing the electronic version of this Prospectus for the purpose of making an investment in the Company, you must be an Australian or New Zealand resident and must only access this Prospectus from within Australia or New Zealand.

No documents or other information available on the Company's website is incorporated into this Prospectus by reference.

The Corporations Act prohibits any person passing onto another person an Application Form unless it is attached to a hard copy of this Prospectus or it accompanies the complete and unaltered version of this Prospectus. You may obtain a hard copy of this Prospectus free of charge by contacting the Company by phone on +61 3 9614 2444 during office hours or by emailing the Company at hydralytecosec@cdplus.com.au.

The Company reserves the right not to accept an Application Form from a person if it has reason to believe that when that person was given access to the electronic Application Form, it was not provided together with the electronic Prospectus and any relevant supplementary or replacement prospectus or any of those documents were incomplete or altered.

1.10 Privacy

The Company collects information (including personal information) in relation to each Applicant as provided on an Application Form (**Information**) for the purposes of processing the Application Form and, should the Application be successful, to administer the Applicant's security holding in the Company, facilitate distribution payment and corporate communications to you as a Shareholder (**Purposes**).

By submitting an Application Form, each Applicant agrees that the Company may use the Information for the Purposes and the Company may disclose the Information for the Purposes to the Share Registry, the Company's related bodies corporate, agents, contractors and third party service providers, and to ASX, ASIC and other regulatory authorities.

The Information may also be used and disclosed to persons inspecting the register, including bidders for your securities in the context of takeovers, licensed securities dealers, mail houses, and regulatory bodies including the Australian Taxation Office.

You can access, correct and update the personal information that we hold about you. Please contact the Company or its share registry if you wish to do so at the relevant contact numbers set out in this Prospectus.

Collection, maintenance and disclosure of certain personal information is governed by legislation including the *Privacy Act 1988* (Cth), the Corporations Act and rules such as the ASX Settlement Operating Rules. You should note that if you do not provide the information required on the application for Shares, the Company may not be able to accept or process your Application.

1.11 Questions

If you have questions about the Offer or how to submit an Application Form, please contact the Company by email at hydralytecosec@cdplus.com.au or via the Share Registry, Automic, on 1300 288 664 (within Australia) and +61 2 9698 5414 (outside Australia) between 8.30 am and 7.00 pm (Melbourne time), Monday to Friday or email corporate.actions@automicgroup.com.au.

1.12 Interpretation

Defined terms and abbreviations used in this Prospectus are explained in Section 9 (*Glossary*).

Unless otherwise stated, references to dollar amounts in this Prospectus are references to Australian dollars (A\$ or AUD). Unless stated otherwise, references to times are references to Melbourne time.

Contents

IMPORTANT NOTICES.....	I
CONTENTS	I
KEY OFFER INFORMATION	2
CHAIRMAN'S LETTER.....	5
1. OFFER OVERVIEW.....	6
2. DETAILS OF THE OFFER.....	11
3. HOW TO APPLY	16
4. PURPOSE AND EFFECT OF THE OFFER.....	19
5. RIGHTS AND LIABILITIES ATTACHING TO SECURITIES.....	25
6. RISK FACTORS.....	30
7. ADDITIONAL INFORMATION	39
8. DIRECTORS' AUTHORISATION.....	49
9. GLOSSARY.....	50

KEY OFFER INFORMATION

KEY DATES	Date
Record date for determining holders of less than a Marketable Parcel (5.00 pm Melbourne time)	Friday 16 October 2026
Announcement of Offer and Share Sale Facility (prior to 10.00 am Melbourne time)	Friday 23 October 2026
Letters sent to holders of less than a Marketable Parcel (prior to 10.00 am Melbourne time)	Friday 23 October 2026
Lodgement of Prospectus with ASIC (prior to 10.00 am Melbourne time)	Friday 23 October 2026
Lodgement of Appendix 3B with ASX (prior to 10.00 am Melbourne time)	Friday 23 October 2026
Ex-date on ASX	Tuesday 27 October 2026
Record Date for determining Entitlements (5.00 pm Melbourne time)	Wednesday 28 October 2026
Prospectus and Entitlement and Acceptance Forms despatched	Monday 2 November 2026
Company announces that dispatch has been completed	Monday 2 November 2026
Opening Date	Monday 2 November 2026
Last day to extend Closing Date (prior to 12.00 pm Melbourne time)	Wednesday 11 November 2026
Closing Date (5.00 pm Melbourne time)	Monday 16 November 2026
Shares quoted on deferred settlement basis	Tuesday 17 November 2026
Announcement of results of the Offer	Thursday 19 November 2026
Issue Date of New Securities	Monday 23 November 2026
Despatch of holding statements	Monday 23 November 2026

KEY DATES	Date
Last day for Company to issue New Securities and lodge Appendix 2A applying for quotation of New Shares (prior to 12.00 pm Melbourne time)	Monday 23 November 2026
New Shares commence trading on ASX	Tuesday 24 November 2026
Closing date for receipt of a Notice of Retention Form (5.00 pm Melbourne time) ("Facility Opt-Out Date")	Monday, 7 December 2026
Sale of less than marketable parcels and distribution of sales proceeds to relevant shareholders	As soon as practicable after the Closing Date for receipt of a Notice of Retention Form
Last day for Company to issue Shortfall Securities	Tuesday 16 February 2027

Notes: The above dates are indicative only. The Directors may extend the Closing Date by giving at least 3 Business Days' notice to ASX prior to the Closing Date. Accordingly, the date the Shares are expected to commence trading on ASX may vary.

KEY OFFER STATISTICS

Issue Price per New Share	\$0.004
Maximum gross proceeds	\$1,434,635
Entitlement Ratio	2 New Shares for every 3 existing Shares
Options Ratio	1 New Option for every 2 New Shares

Existing securities

Current Shares on issue	537,988,485
Current Options on issue (See Note 1)	88,469,890
Current Warrants on Issue	99,942,533

New securities (assuming full subscription)

New Shares to be issued	358,658,990
New Options to be issued (See Note 2)	179,329,495
Broker Options to be issued to Lead Manager (See Note 3)	71,731,798

Post offer securities (assuming full subscription)

Post-offer Shares on issue	896,647,475
Post-offer Options on issue	339,531,183
Post-offer Warrants on issue	99,942,533

Notes:

(1) The Options on issue and to be issued comprise several classes with varying exercise prices and expiry dates.

(2) The New Options (and the Broker Options issuable to the Lead Manager) to be offered under this Prospectus have an exercise price of \$0.006 each and expire on 30 June 2029. The Company intends to apply to ASX for official quotation of the New Options. Quotation is subject to the Company satisfying ASX's quotation requirements (including the requirement for the New Options to be held by at least 50 holders each with a marketable parcel). There is no guarantee that quotation will be granted. If quotation is not granted, the New Options (and the Broker Options) will be issued as unlisted securities and will not be tradeable on ASX. See Sections 2.5 and 5.2(g) for further details.

(3) In addition to the New Options, the Company has agreed to issue 1 option (Broker Option) to Harbour City Corporate (and/or its nominees) in its capacity as Lead Manager for every 5 New Shares issued under the Offer, on the same terms as the New Options. If the Offer is fully subscribed, 71,731,798 Broker Options will be issuable to the Lead Manager. The issue of the Broker Options is subject to Shareholder approval. If Shareholder approval is not obtained, the Company must issue the Broker Options under its ASX Listing Rule 7.1 placement capacity by the deadline specified in the Lead Manager mandate, failing which the Lead Manager may call a cash settlement amount calculated on a Black-Scholes basis. See Sections 7.7 and 7.10 for further details.

Chairman's Letter

Dear Shareholder,

On behalf of the Board of The Hydration Pharmaceuticals Company Limited (ASX: HPC), I am pleased to invite you to participate in the Company's non-renounceable entitlement offer to raise up to approximately **A\$1.4 million** before costs.

The Offer provides eligible shareholders with the opportunity to subscribe for **2 New Shares for every 3 existing Shares** held at the Record Date, at an issue price of **A\$0.004 per Share**, together with **1 free-attaching Option for every 2 New Shares** subscribed for and issued. The Options are exercisable at A\$0.006 and expire on 30 June 2029.

The funds raised will provide additional working capital to support the Company's ongoing operations as we continue to focus on improving financial performance, maintaining cost discipline and strengthening the business for the future.

The capital raising is being led and managed by Harbour City Corporate and is not underwritten.

This Offer provides shareholders with an opportunity to support the Company's next stage of development while maintaining their proportional ownership, should they take up their full entitlement.

In conjunction with the Offer, the Company is also conducting a Share Sale Facility for Shareholders with a registered address in Australia or New Zealand who hold an Unmarketable Parcel of Shares (being a parcel with a market value of less than A\$500) as at the Facility Record Date. Eligible holders will, on an opt-out basis, have their Shares sold on-market by a broker nominated by the Company, with the net sale proceeds remitted to them without brokerage or other transaction costs. Affected Shareholders will receive a separate notice explaining the Facility and how to opt out or, alternatively, how to take up their Entitlement so as to retain a Marketable Parcel. Further details of the Share Sale Facility are set out in Section 2.10 of the accompanying Prospectus.

I encourage you to carefully review the accompanying Prospectus, including the risks associated with an investment in the Company, before making your investment decision.

On behalf of the Board, I sincerely thank you for your continued support and confidence in HPC. We remain committed to building a stronger and more sustainable business and delivering improved outcomes for our shareholders.

Yours sincerely,

Nick Berry
Chairman
The Hydration Pharmaceuticals Company Limited

1. OFFER OVERVIEW

This Section is not intended to provide full information for investors intending to apply for New Shares and New Options offered pursuant to this Prospectus. This Prospectus should be read and considered in its entirety. The New Shares and New Options offered pursuant to this Prospectus carry no guarantee in respect of return of capital, return on investment, payment of dividends or the future value of the Shares.

TOPIC	SUMMARY	WHERE TO FIND MORE INFORMATION
What is the Rights Offer?	The Company is offering Eligible Shareholders the opportunity to subscribe for New Shares and attaching New Options (New Securities) at the Issue Price on a pro-rata basis (the Rights Offer or Offer). The Rights Offer is a non-renounceable pro-rata entitlement offer of 2 New Shares for every 3 existing Shares held on the Record Date, together with 1 free attaching New Option for every 2 New Shares subscribed for and issued. Entitlements are not transferable and will not be quoted on ASX.	Section 2.1
What is the Shortfall Offer?	Any New Securities not subscribed for by Eligible Shareholders under the Rights Offer will constitute a Shortfall. The Company may offer Shortfall Securities to third-party investors and/or existing Shareholders at the Directors' discretion at the same Issue Price as the Rights Offer. The Shortfall Offer is not underwritten.	Section 2.4
Am I an Eligible Shareholder?	You are an Eligible Shareholder if you are registered as a holder of Shares on the Record Date, and you have a registered address in Australia or New Zealand (or such other jurisdictions as the Company determines). Shareholders with a registered address outside Australia and New Zealand may be Ineligible Foreign Shareholders and cannot participate in the Offer.	Section 2.2
What is my Entitlement?	Eligible Shareholders are entitled to subscribe for 2 New Shares for every 3 existing Shares held on the Record Date (rounded down to the nearest whole number of New Shares), together with 1 New Option for every 2 New Shares subscribed for and issued.	Section 2.1

TOPIC	SUMMARY	WHERE TO FIND MORE INFORMATION
	Entitlements will be calculated based on holdings as at the Record Date.	
What can I do?	As an Eligible Shareholder you may: • take up all of your Entitlement; • take up part of your Entitlement; • apply for additional New Securities above your Entitlement under the Shortfall Offer (subject to availability); • take up part of your Entitlement and apply for additional Shortfall Securities; or • do nothing and allow your Entitlement to lapse. Entitlements that are not taken up will lapse and you will not receive any value for them.	Section 2.3
What if I am not an Eligible Shareholder?	If you are not an Eligible Shareholder you cannot participate in the Offer. Your Entitlement will lapse and you will not be entitled to any value for it. Ineligible Shareholders are not able to participate in the Offer.	Section 2.9
How do I accept the Offer?	To accept all or part of your Entitlement, complete the Entitlement and Acceptance Form accompanying this Prospectus and return it together with payment of the Issue Price by the Closing Date.	Full details are set out in Section 3 of this Prospectus.
How will the Shortfall be allocated?	The Directors have absolute discretion as to the allocation of Shortfall Securities. The Directors may allocate Shortfall Securities to any person (including existing Shareholders, Directors and their associates) at the same Issue Price as the Offer, subject to the ASX Listing Rules.	See Section 2.4
Is the Offer underwritten?	No. The Offer is not underwritten. The Company has appointed Harbour City Corporate as Lead Manager for the Offer.	See Sections 2.6 and 2.7 for further details.
What are New Options?	Each New Option entitles the holder to subscribe for one Share at an exercise price of \$0.006 on or before the expiry date of 30 June 2029. The New Options will	Full terms and conditions of the New

TOPIC	SUMMARY	WHERE TO FIND MORE INFORMATION
	be issued for nil consideration as a free attaching incentive to New Shares subscribed for under the Offer, on the basis of 1 New Option for every 2 New Shares subscribed for and issued.	Options are set out in Section 5.2.
What is the purpose of the Offer?	The Company intends to use the proceeds of the Offer to fund general working capital purposes.	Further details regarding the intended use of proceeds are set out in Section 4.2 of this Prospectus.
What effect will the Offer have on the Company?	Assuming full subscription under the Rights Offer, the Offer is expected to raise up to \$1,434,635 (before costs).	The effect of the Offer on the capital structure of the Company, including the number of Shares and Options on issue, is set out in Section 4 of this Prospectus.
What is the effect of the Offer on control of the Company?	Based on current shareholding and Entitlements of Shareholders (including substantial Shareholders) as at the date of this Prospectus, regardless of the amount raised under the Offer, no Shareholder will increase their holding, to an amount in excess of 19.99% through applying for their Entitlements. Further as set out in Section 2.4, on the basis of the allocation policy, no person will acquire, through participation in the Shortfall Offer, Shares if to do so would result in a breach of the takeover prohibitions in Chapter 6 of the Corporations Act or the ASX Listing Rules.	See Section 4.4 for further details.

TOPIC	SUMMARY	WHERE TO FIND MORE INFORMATION
What are the key risks?	Key risks associated with an investment in the Company include: • going concern risk: the Company's ability to continue as a going concern is dependent on generating sufficient cash flow or raising further capital; • loss-making status: the Company has a history of operating losses; • reliance on IP Licence Deed: the Company's ability to commercialise Hydralyte products in the United States depends on the continuation of the IP Licence Deed with Care Pharmaceuticals; no guarantee of quotation of New Options: there is no guarantee that ASX will grant official quotation of the New Options; • US market concentration: operations are concentrated in the United States; • competition: the Company is a small player in a highly competitive market; • brand and reputation: adverse events or publicity could damage the Hydralyte brand; • product liability: the Company may face product liability claims or recalls; • thin liquidity: trading in the Company's Shares has historically been characterised by low volumes; • dilutive capital raising: future equity raisings may further dilute Shareholders.	You should carefully consider the key risks set out in Section 6 of this Prospectus before deciding whether to invest.
What is the Share Sale Facility?	In conjunction with the Offer, the Company has established a share sale facility (Share Sale Facility or Facility) for Shareholders who, as at the Facility Record Date, hold an Unmarketable Parcel of Shares (being, in accordance with the ASX Listing Rules, a parcel of Shares with a market value of less than A\$500). Eligible participating holders (Minority Shareholders) will have their Shares sold on-market by a broker nominated by the Company, without brokerage, and the net sale proceeds remitted to them. Participation is on	Section 2.10

TOPIC	SUMMARY	WHERE TO FIND MORE INFORMATION
-------	---------	--------------------------------

an opt-out basis: a Minority Shareholder will be included in the Facility unless they notify the Company by the Facility Opt-Out Date that they wish to retain their Shares, or take up Entitlements (and, if applicable, apply for Shortfall Securities) sufficient to bring their holding above the Marketable Parcel threshold. The Facility is not available to Shareholders with a registered address outside Australia or New Zealand.

2. DETAILS OF THE OFFER

2.1 The Offer

The Company is offering Eligible Shareholders a non-renounceable pro-rata entitlement offer of New Shares (**Rights Offer**), together with free attaching New Options.

- (a) **Basis of offer:** 2 New Shares for every 3 Shares held at the Record Date.
- (b) **Issue Price:** \$0.004 per New Share, payable in full on application.
- (c) **Attaching options:** For every 2 New Shares subscribed for and issued under the Rights Offer, the subscribing Eligible Shareholder will receive 1 free-attaching New Option.

The Issue Price of \$0.004 represents a premium of approximately 33% to the volume weighted average market price of Shares traded on ASX during the 5 trading days up to and including 22 October 2026.

Entitlements are non-renounceable and are not transferable. They will not be tradeable on ASX or any other exchange.

New Shares issued under the Rights Offer will rank equally in all respects with existing Shares on issue from the date of their allotment.

Fractional entitlements will be rounded down to the nearest whole number of New Shares.

2.2 Eligible Shareholders

To be an Eligible Shareholder and receive an Entitlement under the Rights Offer, a person must satisfy each of the following criteria:

- (a) be a registered holder of Shares as at 5.00 pm (Melbourne time) on the Record Date (28 October 2026);
- (b) have a registered address in Australia or New Zealand at the Record Date; and
- (c) not be located in, and not be a citizen or resident of, any other jurisdiction in which it would be unlawful to extend the Rights Offer.

The Company reserves the right to determine, in its absolute discretion, whether a holder whose registered address is outside Australia or New Zealand is eligible to participate in the Rights Offer, having regard to applicable foreign laws and regulations.

2.3 What Eligible Shareholders may do

Each Eligible Shareholder may elect to do any one of the following in respect of their Entitlement:

- (a) take up their full Entitlement by completing the Entitlement and Acceptance Form and returning it with payment in full;
- (b) take up their full Entitlement and apply for additional New Securities under the Shortfall Offer (see Section 2.4);
- (c) take up part of their Entitlement and allow the balance to lapse; or

- (d) allow their entire Entitlement to lapse without taking any action.

Eligible Shareholders who take no action will be treated as having allowed their entire Entitlement to lapse. Lapsed Entitlements will form part of the Shortfall and may be offered under the Shortfall Offer at the Directors' discretion.

2.4 Shortfall Offer

New Securities not subscribed for under the Rights Offer by the Closing Date will form a Shortfall (**Shortfall Securities**).

Eligible Shareholders who have taken up their full Entitlement may apply for any number of Shortfall Securities in addition to their Entitlement.

The Directors retain absolute discretion over whether to proceed with the Shortfall Offer and over the allocation of Shortfall Securities, including whether to scale back applications.

Shortfall Securities will be issued at the same Issue Price of \$0.004 per New Share. Shortfall Securities may be allocated within 3 months of the Closing Date (and in any event by no later than 16 February 2027).

Priority in any allocation of Shortfall Securities will generally be given to Eligible Shareholders who applied for additional New Securities under the Shortfall Offer, subject to scale-back at the Directors' discretion. The Directors may allocate fewer Shortfall Securities than applied for if total applications for Shortfall Securities exceed the number of Shortfall Securities available.

The Company is not obliged to proceed with the Shortfall Offer and makes no representations about the number of Shortfall Securities that may be available.

Persons who are Associates of the Company under the ASX Listing Rules (including Directors or entities controlled by Directors) are not entitled to participate in the Shortfall Offer without prior Shareholder approval in accordance with ASX Listing Rule 10.11.

If applications for Shortfall Securities exceed the number of Shortfall Securities available, the Directors intend to allocate the Shortfall in consultation with the Lead Manager among Eligible Shareholders proportionate to their existing holdings, subject to scale-back at the Directors' discretion.

The Directors will not allocate Shortfall Securities to any person if to do so would result in a breach of the takeover prohibitions in Chapter 6 of the Corporations Act or the ASX Listing Rules.

The Company will have no liability to any applicant who receives less than the number of Shortfall Securities they applied for under the Shortfall Offer. If the Company scales back any applications for Shortfall Securities under the Shortfall Offer any application monies will be returned (without interest) as soon as practicable.

2.5 Free attaching New Options

In addition to the New Shares offered under the Rights Offer, Eligible Shareholders who subscribe for New Shares will receive free-attaching New Options on the following basis:

- (a) **Entitlement:** 1 New Option for every 2 New Shares subscribed for and issued under the Rights Offer.
- (b) **Exercise Price:** \$0.006 per New Option.

(c) **Expiry Date:** 30 June 2029.

Full terms and conditions of the New Options are set out in Section 5.2 of this Prospectus.

The Company intends to apply to ASX for official quotation of the New Options. The New Options will be unquoted (unlisted) until such time as the Company satisfies the quotation requirements of ASX, which include the New Options being held by at least 50 holders each with a marketable parcel of New Options (being, if all New Options held by a holder were exercised in full, the underlying Shares would be a parcel with a value of not less than A\$500 based on the closing price of the Shares at the time of issue of the New Options). If official quotation of the New Options is not granted, the New Options will be issued as unlisted securities and will not be tradeable on ASX. Nothing in this Prospectus is to be construed as stating or implying that the New Options will be quoted (listed) at any particular time, or at all. Further details of the Company's ASX listing position in respect of the New Options are set out in Section 5.2(g).

New Options are not transferable except in limited circumstances permitted by their terms. Holders of New Options will have no right to participate in any dividend, rights issue or other distribution in respect of Shares unless and until they exercise their New Options.

2.6 Underwriting

The Offer is not underwritten.

2.7 Lead Manager

The Company has appointed Harbour City Corporate as Lead Manager to the Offer. A summary of the material terms of the Lead Manager mandate is set out in Section 7.7 of this Prospectus and the total fees payable are set out in Section 7.10 of this Prospectus.

2.8 Minimum subscription

There is no minimum subscription for the purposes of the Offer. The Offer will proceed regardless of the level of subscriptions received, subject to the conditions of the Offer being satisfied or waived.

2.9 Overseas shareholders

The Rights Offer is made only to Eligible Shareholders. The following restrictions apply to shareholders with addresses outside Australia and New Zealand:

- (a) **Restrictions on foreign offers:** The distribution of this Prospectus in jurisdictions outside Australia and New Zealand may be restricted by law. This Prospectus does not constitute an offer or invitation in any jurisdiction where, or to any person to whom, it would be unlawful to make such an offer or invitation.
- (b) **New Zealand:** The New Securities are not being offered to the public within New Zealand other than to existing shareholders of the Company with registered addresses in New Zealand. The Offer is made to New Zealand shareholders in reliance on relief from the prospectus requirements of the Financial Markets Conduct Act 2013 (NZ) and the Financial Markets Conduct (Incidental Offers) Exemption Notice 2021 (New Zealand). This Prospectus has been prepared in compliance with Australian law and has not been registered, filed with or approved by any New Zealand regulatory authority. This Prospectus is not a product disclosure statement for the purposes of the Financial Markets Conduct Act 2013 (NZ) and is not required to, and may not, contain

all the information that a product disclosure statement under New Zealand law is required to contain.

- (c) **Nominees and custodians:** Nominees, custodians and other persons who hold Shares on behalf of foreign beneficial holders must not distribute this Prospectus or the Entitlement and Acceptance Form to those beneficial holders, and must not arrange for New Securities to be issued to those beneficial holders, unless it is lawful to do so in the relevant jurisdiction and the Company has confirmed in writing that it consents to such distribution or issue.
- (d) **Ineligible Shareholders:** Shareholders whose registered address is outside Australia and New Zealand and who have not been determined by the Company to be Eligible Shareholders (**Ineligible Shareholders**) will not receive an Entitlement. Their Entitlements will lapse and will form part of the Shortfall. Ineligible Shareholders will not receive any payment or other consideration in respect of lapsed Entitlements.

2.10 Share Sale Facility

In conjunction with the Offer, the Company has established a share sale facility (**Facility**) to allow Shareholders who hold an Unmarketable Parcel of Shares as at the Facility Record Date the opportunity to sell their Shares on-market without incurring brokerage or other transaction costs. The Facility is being conducted under rule 5.4 (*Selling non marketable parcels*) of the Constitution, which authorises the Board to sell Shares that constitute less than a marketable parcel by following the procedures set out in that rule.

- (a) **Unmarketable Parcel:** The ASX Listing Rules define a marketable parcel as a parcel of Shares with a market value of at least A\$500. As at the Facility Record Date, being 5.00 pm (Melbourne time) on 16 October 2026, and based on the closing sale price of Shares on ASX on that date of \$0.003, an Unmarketable Parcel is any holding of fewer than 166,667 Shares. As at that date, approximately 436 Shareholders held an Unmarketable Parcel of Shares, representing approximately 3.47% of the total Shares on issue (**Minority Shareholders**).
- (b) **Eligibility:** The Facility is available only to Minority Shareholders with a registered address in Australia or New Zealand. Consistent with the restrictions on the Offer set out in Section 2.9, the Facility is not available to Shareholders whose registered address is outside Australia or New Zealand.
- (c) **Notice under rule 5.4(b) and opt-out:** In accordance with rule 5.4(b) of the Constitution, each Minority Shareholder will be sent a notice explaining the effect of rule 5.4 and enclosing a form by which the Minority Shareholder may elect to be exempt from the Facility. As required by rule 5.4(c), the deadline for opting out is 5.00 pm (Melbourne time) on the Facility Opt-Out Date, being a date not earlier than 6 weeks after the notice is sent. A Minority Shareholder will be included in the Facility and taken to have irrevocably appointed the Company as their agent to sell their Shares unless, by the Facility Opt-Out Date, the Minority Shareholder either:
 - (i) returns the retention form notifying the Company that they wish to be exempt from rule 5.4 and retain their Shares; or
 - (ii) takes up their Entitlement under the Rights Offer (and, if applicable, applies for additional Shortfall Securities), merges multiple holdings or acquires more shares in the Company on the market, so that their resulting shareholding as at the Facility Opt-Out Date is a Marketable Parcel.
- (d) **Sale process:** The Shares of Minority Shareholders who have not opted out and remain eligible as at the Facility Opt-Out Date will be sold on-market by the Company's nominated broker (**Nominated Broker**) as soon as practicable during the sale period

set out in the Key Dates table. Sales will be at prevailing market prices and Shares may be sold in one or more transactions over the sale period. The average sale price achieved (and therefore the proceeds returned to each Minority Shareholder) will depend on market conditions during the sale period. Neither the Company nor the Nominated Broker guarantees any minimum sale price.

- (e) **No cost to Minority Shareholders:** The costs and expenses of any sale under the Facility, including brokerage and any stamp duty, will be met by the Company (rule 5.4(f) of the Constitution). No brokerage, commission or other transaction costs will be payable by Minority Shareholders in respect of the sale of their Shares under the Facility.
- (f) **Payment of proceeds:** The net proceeds of sale attributable to each Minority Shareholder will be applied and paid in accordance with rules 3.8 and 5.4(e) of the Constitution, and will be remitted (without interest) by direct credit to the bank account recorded on the Company's share register (or as otherwise provided) as soon as reasonably practicable after the end of the sale period and required bank details are received, and in any event by the date shown in the Key Dates table.
- (g) **Rights Offer interaction:** Minority Shareholders who are also Eligible Shareholders are entitled to take up their Entitlement under the Rights Offer in the manner described in Section 3, notwithstanding that they hold an Unmarketable Parcel. Taking up an Entitlement in respect of a sufficient number of New Shares to bring the resulting holding above the Marketable Parcel threshold as at the Facility Opt-Out Date will remove that Shareholder from the Facility.
- (h) **Once in 12 months / takeover bid:** In accordance with rule 5.4(g) of the Constitution, a notice under rule 5.4(b) may be given to a Minority Shareholder only once in any 12-month period and may not be given during the offer period of a takeover bid for the Company. If a takeover bid is announced after the notice is sent but before an agreement is entered into for the sale of the Shares, rule 5.4(h) provides that rule 5.4 ceases to operate in respect of those Shares (and the Facility will accordingly not proceed in respect of those Shares).
- (i) **Discretion:** The Board reserves the right, in accordance with rule 5.4(i) of the Constitution and before a sale is effected, to revoke any notice given, or to suspend or terminate the operation of the Facility either generally or in specific cases, in its absolute discretion, including where the Board considers that market conditions would result in an unsatisfactory sale price for Minority Shareholders.

Further information about the Facility (including the process for opting out and detailed sale mechanics) is set out in the Company's ASX announcement dated 23 October 2026 and the notice under rule 5.4(b) of the Constitution accompanying this Prospectus sent to Minority Shareholders.

3. HOW TO APPLY

3.1 Applying for New Securities

Eligible Shareholders who wish to take up all or part of their Entitlement and/or apply for Shortfall Securities must do so in one of the following ways:

- (a) apply via BPAY using the Biller Code and unique Reference Number printed on the personalised Entitlement and Acceptance Form (see Section 3.2); or
- (b) apply via EFT to the bank account details set out on the personalised Entitlement and Acceptance Form (see Section 3.2).

Applications must be received by the Share Registry by no later than 5.00 pm (Melbourne time) on the Closing Date (16 November 2026). Applications received after this time may not be accepted.

You do not need to submit the Entitlement and Acceptance Form but, by lodging an application or making payment, each applicant is taken to have made the declarations on that Entitlement and Acceptance Form and makes a binding and irrevocable offer to subscribe for New Securities on the terms and conditions set out in this Prospectus.

3.2 Payment

All payments must be made in Australian dollars. The following payment methods are accepted:

BPAY Biller Code: as printed on your personalised Entitlement and Acceptance Form.

BPAY Reference Number (CRN): as printed on your personalised Entitlement and Acceptance Form.

Payments must be made from an Australian dollar bank account. Ensure that sufficient cleared funds are available by the Closing Date. Your financial institution may impose an earlier cut-off for BPAY payments; please confirm with your financial institution.

EFT Please follow the instructions on the Entitlement and Acceptance Form and quote your unique entitlement reference number (as printed on your Entitlement and Acceptance Form) as the payment reference so that your payment can be identified.

Cash will not be accepted. The Company will not be responsible for payments lost in transit. Applicants are responsible for ensuring that payment is received by the Share Registry by the Closing Date. Applications for which cleared funds have not been received by the Closing Date may be rejected.

3.3 Multiple holdings

If you hold Shares in more than one capacity or in more than one registered holding, you will receive a separate personalised Entitlement and Acceptance Form for each holding.

- (a) Each holding has a unique Reference Number printed on its Entitlement and Acceptance Form.
- (b) You must use the correct Reference Number for each individual holding when making payment. Failure to do so may result in your application not being correctly processed.
- (c) You must lodge a separate application and payment in respect of each individual holding.

3.4 Implications of acceptance

By lodging an application and making payment, each applicant is taken to have represented, warranted and agreed as follows:

- (a) The applicant has read and understood this Prospectus in full and agrees to be bound by its terms and conditions.
- (b) The applicant agrees to be bound by the Constitution of the Company and the ASX Listing Rules.
- (c) The applicant is not in the United States and is not acting for the account or benefit of a US Person (as defined in Regulation S under the US Securities Act of 1933, as amended).
- (d) The applicant is an Eligible Shareholder and is entitled to receive New Securities under the Offer.
- (e) The applicant authorises the Company to register the applicant (or such other person as the applicant directs) as the holder of the New Securities issued to the applicant.
- (f) All information provided by the applicant in connection with the application is true, complete and not misleading, and the applicant consents to the Company using that information in connection with the Offer.
- (g) The applicant acknowledges that the Company and its officers, employees and agents are not liable for any consequences of the exercise or non-exercise of their discretions referred to in this Prospectus, including in relation to the allocation of Shortfall Securities.
- (h) The applicant acknowledges that the information contained in or accompanying this Prospectus is not, and none of the Company, its officers, advisers or agents has provided the applicant with, any investment or financial product advice or a recommendation that the New Securities are suitable for the applicant given the applicant's investment objectives, financial situation or particular needs.
- (i) The applicant authorises the Company and its officers and agents to do anything on the applicant's behalf necessary for the New Securities to be issued to the applicant, including correcting errors in or omissions from the applicant's Application Form.
- (j) The applicant acknowledges that the New Securities have not been, and will not be, registered under the securities laws of any jurisdiction outside Australia and New Zealand and accordingly may not be offered, sold or otherwise transferred except in accordance with an available exemption from, or in a transaction not subject to, the registration requirements of applicable securities laws.

3.5 Binding effect

Each application under the Offer is irrevocable and unconditional. Once lodged, an application may not be withdrawn except as required by law. The Company is not obliged to

accept any application (in whole or in part) and may, at its discretion, reject or scale back any application for Shortfall Securities. Where an application is rejected or scaled back, application monies in respect of the rejected or scaled-back portion will be refunded to the applicant without interest.

3.6 Application moneys

Pending the issue of the New Securities, or payment of refunds pursuant to this Prospectus, Application Moneys will be held by the Company on trust for the Applicants in a separate bank account in accordance with the requirements of the Corporations Act. The Company is entitled to retain any interest earned on Application Moneys in that bank account, including in the event of any refund of Application Moneys, and each Applicant waives the right to claim interest.

If the number of New Securities issued to an Applicant is less than the number applied for, the surplus Application Moneys will be refunded without interest to the Applicant as soon as practicable after the Closing Date or the issue of New Securities under the Shortfall Offer, as applicable.

3.7 No brokerage

No brokerage, commission, stamp duty or other transaction costs are payable by Applicants in respect of applications for, or the issue of, New Securities under the Offer.

3.8 CHESS and issuer sponsorship

The Company participates in the Clearing House Electronic Sub-register System (**CHESS**), operated by ASX Settlement Pty Ltd (a wholly owned subsidiary of ASX), in accordance with the ASX Listing Rules and ASX Settlement Operating Rules. The Company operates an electronic issuer-sponsored sub-register and an electronic CHESS sub-register. The two sub-registers together make up the Company's principal register of Securities.

Under CHESS, you will not receive a certificate but will receive a holding statement (similar to a bank account statement). The CHESS statement will set out the number of New Securities allotted to you under this Prospectus and details of your Holder Identification Number (**HIN**).

If you do not wish to participate through CHESS, you will be issuer sponsored by the Company and will be registered on the electronic issuer-sponsored sub-register. Your statement will be issued by the Share Registry and will set out the number of New Securities allotted to you under this Prospectus and details of your Security Holder Reference Number (**SRN**).

A statement will be routinely sent to holders following the end of any calendar month during which their holding changes. A holder may request a statement at any other time; however, a charge may be incurred for additional statements.

3.9 Queries

Any queries regarding the Offer should be directed to the Company Secretary at hydralytecosec@cdplus.com.au.

Any queries regarding the Entitlement and Acceptance Form should be directed to the Share Registry, Automic, on 1300 288 664 (within Australia) and +61 2 9698 5414 (outside Australia) between 8.30 am and 7.00 pm (Melbourne time), Monday to Friday or email corporate.actions@automicgroup.com.au.

4. PURPOSE AND EFFECT OF THE OFFER

4.1 Purpose of the Offer

The purpose of the Offer is to raise up to approximately \$1.4 million (before costs).

4.2 Use of proceeds

The Company proposes to use the funds raised from the Offer (assuming full subscription) as follows:

Use of Funds	Amount (\$) (full subscription)	%
Working capital	\$1,277,240	89%
Costs of the Offer	\$157,395	11%
Total	\$1,434,635	100%

The Offer is not underwritten and there is no minimum subscription. In the event that less than the full subscription amount is raised under the Offer, the Company will apply the funds raised in the following order of priority:

- (a) first, to meet the costs of the Offer (which are largely fixed regardless of the level of subscription);
- (b) second, to fund the Company's ongoing working capital requirements, including the compliance costs of the entity, inventory purchases and other fixed costs of the business; and
- (c) third, to the extent funds remain, to identify discretionary expenditure to drive growth, including marketing and sales initiatives and product development.

If the Offer raises significantly less than the full subscription amount, the Company may need to scale back or defer discretionary expenditure and may need to seek additional funding from other sources. There is no assurance that alternative funding will be available on acceptable terms, or at all. Shareholders should refer to the going concern risk factor set out in Section 6 of this Prospectus.

The table below sets out the Board's current intentions regarding the allocation of proceeds under different subscription scenarios:

Use of Funds	Amount (\$) (75% subscription)	%	Amount (\$) (50% subscription)	%	Amount (\$) (25% subscription)	%
Working capital	\$942,598	87.6%	\$607,976	84.8%	\$273,353	76.2%
Costs of the Offer	\$133,378	12.4%	\$109,342	15.2%	\$85,306	23.8%
Total	\$1,075,976	100%	\$717,318	100%	\$358,659	100%

The Board is of the view that, assuming full subscription under the Offer, the net proceeds of the Offer together with the Company's existing cash reserves will provide sufficient working capital to fund the Company's operations for a period of at least 18 months from the date of this Prospectus. If less than the full subscription amount is raised, the period for which the Company's working capital requirements are funded will be correspondingly reduced. In such circumstances, the Company may need to raise additional capital and/or reduce its operating expenditure. There is no assurance that additional capital will be available on acceptable terms, or at all.

The Company expects to deploy the net proceeds of the Offer over the 18 month period following the Closing Date. The costs of the Offer are expected to be incurred in full within 2 months of the date of this Prospectus. Working capital expenditure is expected to be deployed on an ongoing basis to fund the Company's day-to-day operations.

The actual timing of expenditure may differ from the above estimates depending on a number of factors, including the level of subscription achieved under the Offer, the Company's operating performance, changes in market conditions, and any opportunities or challenges that arise. The Board retains discretion to reallocate funds as it considers appropriate in the best interests of the Company and its Shareholders.

4.3 Effect on capital structure

Shares

	Number of Shares
Shares currently on issue	537,988,485
New Shares to be issued under the Offer (maximum)	358,658,990
Total Shares on issue after completion of the Offer (maximum)	896,647,475

Options

	Number of Options
Options currently on issue (See Note 1)	88,469,890
New Options to be issued under the Offer (maximum)	179,329,495 (See Note 2)
Broker Options to be issued to Lead Manager (See Note 3)	71,731,798
<i>Total Options on issue after completion of the Offer (maximum)</i>	<i>339,531,183</i>

Notes:

(1) The Options on issue and to be issued comprise several classes with varying exercise prices and expiry dates.

(2) The New Options to be offered under this Prospectus have an exercise price of \$0.006 each and expire on 30 June 2029. The Company intends to apply to ASX for official quotation of the New Options. Quotation is subject to the Company satisfying ASX's quotation requirements (including the 50-holder marketable parcel test). If quotation is not granted, the New Options will be issued as unlisted securities and will not be tradeable on ASX. See Sections 2.5 and 5.2(g) for further details.

(3) The Broker Options to be issued to the Lead Manager (Harbour City Corporate) are on the same terms as the New Options. They will be issued on the basis of 1 Broker Option for every 5 New Shares issued under the Offer, subject to Shareholder approval. If Shareholder approval is not obtained, the Company must issue the Broker Options under its ASX Listing Rule 7.1 placement capacity by the deadline specified in the Lead Manager mandate, failing which the Lead Manager may elect for a cash settlement calculated on a Black-Scholes basis. See Section 7.7 for further details of the Lead Manager mandate.

Warrants

	Number of Warrants
Warrants currently on issue	99,942,533
New Warrants to be issued under the Offer	Nil
Total Warrants on issue after completion of the Offer (maximum)	99,942,533

4.4 Effect on control

The Company does not consider that the Offer will have a material effect on the control of the Company. The Offer is being made on a pro-rata basis to all eligible Shareholders, which is intended to maintain existing proportional shareholdings (subject to Shareholders electing whether or not to take up their Entitlements).

If any Director or substantial holder of the Company participates in the Offer (including by taking up shortfall Shares), this may have potential control effects on the Company.

PURE Asset Management Pty Ltd as trustee for The Pure Income and Growth Fund (PURE) has confirmed to the Company in writing that it does not intend to exercise any of the 52,442,532 Warrants in which it (and, through it, Mr Berry) has a relevant interest prior to the Record Date. On that basis, Mr Berry's voting power will not increase as a result of any exercise of Warrants before the Record Date, and (assuming full subscription under the Offer and no allocation of Shortfall Securities to PURE or any other substantial holder in a manner that would take their voting power above 20%) completion of the Offer is not expected to result in any person acquiring voting power in the Company exceeding the threshold set by section 606 of the Corporations Act. The Company does not intend to allocate Shortfall Securities to any substantial Shareholder in a manner that would cause the acquirer's voting power to exceed 19.99%.

As the Offer is a non-renounceable entitlement offer, Shareholders who do not take up their Entitlement in full will have their proportional shareholding in the Company diluted. Shareholders who are not eligible to participate in the Offer will also be diluted.

4.5 Potential dilution

The table below illustrates the potential dilution effect of the Offer on Shareholders who do not take up their full Entitlement. The dilution figures below are calculated on the basis that the Offer is fully subscribed (i.e., all Shareholders take up their Entitlements) except for the Shareholder whose dilution is being illustrated. The dilution figures are presented on an undiluted basis (excluding the effect of Options and Warrants on issue). If all Options and Warrants currently on issue were exercised prior to the Record Date, the dilution effect for non-participating Shareholders would differ from that shown below. Shareholders who do not take up their full Entitlement will have their percentage interest in the Company diluted by up to approximately 40%.

Shareholder's holding at Record Date	Entitlements under the Offer	Holdings if Entitlements not taken up	% dilution
53,798,848 Shares (10.00%)	35,865,898 New Shares 17,932,949 New Options	53,798,848 Shares (6.00%)	40.00%
26,899,424 Shares (5.00%)	17,932,949 New Shares 8,966,474 New Options	26,899,424 Shares (3.00%)	40.00%
5,379,884 Shares (1.00%)	3,586,589 New Shares 1,793,294 New Options	5,379,884 Shares (0.60%)	40.00%

The dilution effect shown above is the maximum dilution that would be experienced by a Shareholder if they did not take up any of their Entitlement and the Offer was fully subscribed by all other Shareholders. The actual dilution will depend on the number of Entitlements taken up by Shareholders.

The dilution figures shown above do not take into account the effect of any Options or Warrants currently on issue, the New Options to be issued under the Offer, or the Broker Options to be issued to the Lead Manager (Harbour City Corporate). In addition to the dilution shown above, if the Broker Options are issued (which is subject to Shareholder approval, with a fallback to the Company's ASX Listing Rule 7.1 placement capacity) and subsequently exercised, Shareholders who do not take up their Entitlement would experience further dilution. If the Offer is fully subscribed, up to 71,731,798 Broker Options may be issued to the Lead Manager on the same terms as the New Options, representing approximately a further 8.0% of the post-Offer issued Shares on a fully diluted basis if all Broker Options are exercised. See Section 7.7 for further details of the Broker Options and the Lead Manager mandate.

4.6 Pro forma consolidated statement of financial position

The reviewed (unaudited) consolidated statement of financial position as at 30 June 2026 and the unaudited pro-forma consolidated statement of financial position as at 30 June 2026 shown below have been prepared on the basis of the accounting policies normally adopted by the Company and reflect the changes to its financial position.

The pro-forma consolidated statement of financial position has been prepared assuming all Entitlements are accepted, no Options or Warrants are exercised prior to the Record Date and including expenses of the Offer.

The pro-forma consolidated statement of financial position has been prepared to provide investors with information on the assets and liabilities of the Company and pro-forma assets and liabilities of the Company as noted below.

The historical reviewed (unaudited) consolidated statement of financial position as at 30 June 2026 is reported in US dollars. For the purposes of this Prospectus, the historical balances have been translated and presented in Australian dollars to align with the currency of the Offer. The translation has been made using a reference exchange rate of A\$1.00 = US\$0.6917 (equivalent to US\$1.00 = A\$1.4457) as at 30 June 2026. The reference rate is based on the Reserve Bank of Australia daily exchange-rate series. The Australian-dollar presentation is for Prospectus and pro forma purposes only and does not alter the Company's underlying US-dollar historical financial statements.

The historical and pro-forma financial information is presented in an abbreviated form, insofar as it does not include all of the disclosures required by Australian Accounting Standards applicable to annual financial statements.

	30 June 2026 Actual (A\$)	Capital Raise Adjustment (A\$)	Offer Costs Adjustment (A\$)	Pro Forma (A\$)
ASSETS				
CURRENT ASSETS				
Cash and cash equivalents	640,334	1,434,635	(157,395)	1,917,574
Trade and other receivables	116,798	-	-	116,798
Inventories	879,237	-	-	879,237
Other assets	153,545	-	-	153,545
TOTAL CURRENT ASSETS	1,789,913	1,434,635	(157,395)	3,067,153
NON-CURRENT ASSETS				
TOTAL NON-CURRENT ASSETS	-	-	-	-
TOTAL ASSETS	1,789,913	1,434,635	(157,395)	3,067,153
LIABILITIES				
CURRENT LIABILITIES				
Trade and other payables	776,316	-	-	776,316
Derivative financial instruments	64,795	-	-	64,795
TOTAL CURRENT LIABILITIES	841,112	-	-	841,112
NON-CURRENT LIABILITIES				
TOTAL NON-CURRENT LIABILITIES	-	-	-	-
TOTAL LIABILITIES	841,112	-	-	841,112
NET ASSETS	948,802	1,434,635	(157,395)	2,226,042
EQUITY				
Contributed equity	59,279,092	1,434,635	(157,395)	60,556,332
Reserves	5,756,247	-	-	5,756,247
Accumulated losses	(64,086,538)	-	-	(64,086,538)
TOTAL EQUITY	948,802	1,434,635	(157,395)	2,226,042

5. RIGHTS AND LIABILITIES ATTACHING TO SECURITIES

5.1 Rights attaching to New Shares

The New Shares to be issued under this Prospectus will rank equally with the existing fully paid ordinary shares in the Company.

The rights attaching to shares are set out in the Company's constitution, and, in certain circumstances, are regulated by the Corporations Act, the ASX Listing Rules and general law. The constitution of the Company may be inspected during normal business hours at the registered office of the Company.

The following is a summary of the principal rights of the holders of ordinary shares of the Company. This summary is not exhaustive nor does it constitute a definitive statement of the rights and liabilities of the Company's members.

(a) General meeting and notices

Each member is entitled to receive notice of, and to attend and vote at, general meetings of the Company and to receive all notices, accounts and other documents required to be sent to members under the Company's constitution, the Corporations Act or the Listing Rules.

(b) Voting rights

Subject to any rights or restrictions for the time being attached to any class or classes of shares, at a general meeting of the Company every holder of fully paid ordinary shares present in person or by an attorney, representative or proxy has one (1) vote on a show of hands and one (1) vote per share on a poll.

A person who holds a share which is not fully paid is entitled, on a poll, only to the fraction of one vote which the amount paid (not credited) on the share bears to the total amounts paid and payable (excluding amounts credited) on the share. An amount paid in advance of a call is disregarded for this purpose.

Where there are 2 or more joint holders of a share, only the joint holder whose name appears first in the register who tenders a vote, whether in person or by proxy, attorney or Representative, is entitled to vote, to the exclusion of the votes of the other joint holders.

(c) Issues of further shares

The Directors may:

- (i) issue or dispose of shares to any person at any time and on any terms and conditions and having attached to them any preferred, deferred or other special rights or restrictions, whether with regard to dividend, voting, return of capital or otherwise, as the Directors think; and
- (ii) grant to any person an option over shares or pre-emptive rights at any time and for any consideration as they think fit.

The Directors must ensure that the issue of securities following the exercise, conversion or paying up of any security of the Company quoted by ASX is not in any way prevented, delayed or interfered with by the Company except as permitted by the Listing Rules.

(d) Variation of rights

At present, the Company has on issue one (1) class of shares only, namely ordinary shares.

The Company may vary or cancel the rights attaching to any class of shares with the written consent of the holders of 75% of the shares of the class, or by a special resolution passed at a separate meeting of the holders of shares of the class (unless the terms of issue of those shares state otherwise).

(e) Transfer of shares

Subject to the Company's constitution, the Corporations Act and the ASX Listing Rules, ordinary shares are freely transferable.

Subject to the Corporations Act, the ASX Listing Rules or the Operating Rules, Shares are transferable by an instrument of transfer in writing in any usual or common form or in any other form that the Directors approve.

The Board may decline to register, or prevent registration of, a transfer of shares or apply a holding lock to prevent a transfer in accordance with the Corporations Act or the ASX Listing Rules where: (i) the transfer is not in registrable form; (ii) the Company has a lien on any of the shares transferred; (iii) registration of the transfer may breach a law of Australia; (iv) the transfer is paper-based and registration of the transfer will result in a holding which, at the time the transfer is lodged, is less than a marketable parcel; (v) the transfer is not permitted under the terms of an employee share plan; or (vi) the Company is otherwise permitted or required to do so under the Listing Rules or, except for a Proper ASTC Transfer, under the terms of issue of the shares. If the Board refuses to register a transfer, the Company must give notice of the refusal as required by the Corporations Act and the ASX Listing Rules.

(f) Dividends

Subject to the Company's constitution and the Corporations Act, the Board may resolve to pay any dividend it thinks appropriate and fix the time for payment. Subject to the terms of issue of shares, the Company may pay a dividend on one class of shares to the exclusion of another class.

Subject to any rights or restrictions attached to any shares or class of shares, all dividends must be paid equally on all shares, except that a partly paid share confers an entitlement only to the proportion of the dividend which the amount paid (not credited) on the share is of the total amounts paid and payable (excluding amounts credited) on the share. Unless the Board decides otherwise, an amount paid on a share in advance of a call is to be taken as not having been paid until it becomes payable.

(g) Winding up

Subject to the Company's constitution, the Corporations Act and to the terms of issue of the shares, if the Company is wound up and the property of the Company available is more than sufficient to pay (i) all the debts and liabilities of the Company; and (ii) the costs, charges and expenses of the winding up, the excess must be divided among the Members in proportion to the number of shares held by them, irrespective of the amounts paid or credited as paid on the shares.

(h) Dividend reinvestment and share plans

The Board may adopt and implement dividend reinvestment plans (under which any member may elect that dividends payable by the Company be reinvested by way of subscription for fully paid shares in the Company) and any other share plans (under which any member may elect to forego any dividends that may be payable on all or some of the shares held by that member and to receive instead some other entitlement, including the issue of fully paid shares).

(i) Directors

The Company's constitution states that the number of directors (not including alternate directors) shall not be less than 3 and not be more than 9, unless the Company resolves otherwise at a general meeting.

(j) Powers of the Board

Except as otherwise required by the Corporations Act, any other law, the ASX Listing Rules or the Company's constitution, the business and affairs of the Company are to be managed by or under the direction of the Board, which may exercise all powers and do all things that are within the power of the Company and are not by the constitution or by law directed or required to be done by the Company in general meeting.

5.2 Terms and conditions of New Options

The following are the full terms and conditions of the New Options to be issued pursuant to the Offer. The Broker Options to be issued to the Lead Manager (Harbour City Corporate) under the Lead Manager mandate are of the same class as, and rank *pari passu* with, the New Options, and are on the same terms and conditions as those set out in this Section 5.2 (including as to exercise price, expiry date, nil vesting conditions and quotation). The issue of the Broker Options is subject to Shareholder approval, with a fallback mechanic for issue under the Company's ASX Listing Rule 7.1 placement capacity. See Sections 7.7 and 7.10 for further details.

(a) Entitlement

Each New Option entitles the holder to subscribe for 1 Share upon exercise of the New Option.

(b) Exercise Price

The exercise price of each New Option is \$0.006 per New Option (**Exercise Price**).

(c) Expiry Date

Each New Option will expire at 5.00 pm (Melbourne time) on 30 June 2029 (**Expiry Date**). New Options not exercised on or before the Expiry Date will lapse automatically.

(d) Exercise Period

Each New Option is exercisable at any time on or before the Expiry Date.

(e) Exercise Notice

New Options may be exercised by the delivery of a written exercise notice to the Company in the form prescribed by the Company from time to time, together with payment of the Exercise Price in full in respect of each New Option exercised. An exercise notice is only effective when the Company receives it together with cleared payment of the Exercise Price.

(f) Timing of Issue of Shares on Exercise

The Company will issue the relevant number of Shares to the holder within 5 Business Days of receiving a valid exercise notice and payment of the Exercise Price in full.

(g) Quotation

The Company intends to apply to ASX for official quotation of the New Options, subject to ASX's quotation requirements for a new class of securities being satisfied (including the requirement for the New Options to be held by at least 50 holders each with a marketable parcel). The New Options will be unquoted (unlisted) until such time as the Company satisfies the quotation requirements of ASX.

If official quotation of the New Options is not granted, the New Options will nevertheless be issued to Eligible Shareholders (and the Lead Manager, in respect of the Broker Options) who have validly applied, but will be unlisted and will not be tradeable on ASX. Nothing in this Prospectus is to be construed as stating or implying that the New Options will be quoted (listed) at any particular time, or at all. The terms and conditions of the New Options set out in this Section 5.2 (including as to exercise price, expiry date, exercise mechanics, transferability and the issue of Shares on exercise) will apply in the same way whether or not the New Options are quoted. In all cases, the Company will apply to ASX for official quotation of the Shares issued on exercise of the New Options (subject to the Company remaining admitted to the official list of ASX at the relevant time).

(h) Transferability

Options are transferable subject to the Corporations Act and the ASX Listing Rules.

(i) Participation Rights

New Options do not confer on the holder any right to participate in new issues of securities of the Company without first exercising the New Options.

(j) Adjustment for Bonus Issues

If the Company makes a bonus issue of Shares or other securities to existing holders of Shares (other than an issue in lieu of dividends or by way of dividend reinvestment), the number of Shares which must be issued on the exercise of each New Option will be increased by the number of Shares which the holder would have received if the New Option had been exercised before the record date for the bonus issue.

(k) Reorganisation of Capital

If there is any reorganisation of the issued capital of the Company (including a consolidation, subdivision, reduction, or return), the number of New Options, the

Exercise Price, or both, will be adjusted in accordance with the ASX Listing Rules applicable to a reorganisation of capital at the time of the reorganisation.

(l) Pro-Rata Issues

In the event the Company makes a pro rata issue of securities (other than a bonus issue) to the holders of Shares, the Exercise Price of the New Options may be reduced in accordance with the formula set out in ASX Listing Rule 6.22.2.

(m) Dividend Rights

New Options do not confer any right to receive dividends. The holder will not be entitled to any dividends until Shares are issued upon exercise of the New Options and the holder becomes a registered Shareholder.

(n) Voting Rights

New Options do not confer any right to vote at general meetings of the Company. The holder will not be entitled to vote until Shares are issued upon exercise of the New Options and the holder becomes a registered Shareholder.

6. RISK FACTORS

6.1 Introduction

Investment in the Company is speculative and involves a number of risks. Prospective investors and their professional advisers should carefully consider the risk factors set out below, together with all other information contained in this Prospectus, before deciding whether to apply for Securities.

The risks set out below are not exhaustive. There may be additional risks and uncertainties not presently known to the Company, or that the Company currently considers immaterial, which may also have an adverse effect on the Company.

Prospective investors should seek independent professional advice, including financial, legal and taxation advice, before making an investment decision.

6.2 Company specific risks

Risk Category	Risk Description
Going concern risk	The ability of the Company to continue as a going concern is dependent on its ability to generate sufficient cash flow from its operations or to raise further capital. There is no guarantee that the Company will be able to do so on terms acceptable to it, or at all. The Company has incurred significant losses since inception. The historical reviewed statement of financial position as at 30 June 2026, set out in Section 4.6, shows accumulated losses of approximately A\$64.08 million and net assets of a materially lower amount. Those accumulated losses are not reduced by the Offer and will continue to appear on the Company's balance sheet following completion of the Offer. The Offer is expected to increase the Company's cash reserves and net assets by the net proceeds of the Offer (approximately A\$1.28 million assuming full subscription, as set out in Section 4.6), but this increase is small relative to the accumulated losses and does not, of itself, remove any going concern uncertainty. In addition, the Offer is not underwritten and has no minimum subscription amount (see Section 2.8). If the Offer raises materially less than the full subscription amount, or if the Company's operating cash flow deteriorates further, the Company's existing cash reserves (together with any net proceeds of the Offer actually received) may be insufficient to fund its operations for the period described in Section 4.2, and the Company may need to raise further capital, scale back or defer discretionary expenditure, dispose of assets, or (in the worst case) cease operating. There is no assurance that any such further capital raising will be available on acceptable terms, or at all.

Shareholders should read this risk factor together with Section 4.6 (Pro Forma Consolidated Statement of Financial Position) and the Loss-making status risk factor set out immediately below.

Loss-making status	The Company has a history of operating losses and has accumulated significant losses since inception. There is no assurance that the Company will achieve or sustain profitability in the future. The Company's ability to continue as a going concern is dependent on its capacity to generate sufficient revenue from its operations, manage its cost base, and, if necessary, raise additional capital. If the Company is unable to achieve profitability or secure additional funding, it may be required to scale back its operations, dispose of assets, or cease operating. Shareholders should consider this risk in light of the Company's historical financial performance and the going-concern risk factor set out above.
--------------------	--

Reliance on IP Licence Deed	The Company's ability to commercialise Hydralyte products in the United States is dependent on the continuation of its intellectual property licence arrangements. The Company has access to certain of its intellectual property through the IP Licence Deed with Prestige Consumer Healthcare Inc (via its subsidiary Care Pharmaceuticals Pty Limited). The IP Licence Deed grants the Company a perpetual, irrevocable, royalty-free licence to use the licensed IP to sell its products on an exclusive basis, and to manufacture, modify, adapt and otherwise exploit the products on a non-exclusive basis, in the United States.
-----------------------------	---

While the IP Licence Deed is irrevocable and does not contain express termination rights, there is a risk that Care Pharmaceuticals may seek to terminate the agreement following a material breach by the Company. The Company and Care Pharmaceuticals each have responsibilities to protect unregistered intellectual property through confidentiality, and a significant failure by the Company to enforce its intellectual property rights may also cause Care Pharmaceuticals to seek to terminate the IP Licence Deed. If the IP Licence Deed were terminated and such termination were held to be valid, this would have a material detrimental impact on the Company's branding, reputation, future prospects and financial performance.

US market concentration	The Company's operations are concentrated exclusively in the United States, operating as a wholesale supplier and online retailer of Hydralyte products. The Company is restricted from being involved in a competing business worldwide other than in the United States, which limits the Company's future growth options and geographic diversification. This geographic concentration exposes the Company to risks specific to the US market, including changes in consumer preferences, competition from established beverage and hydration brands, regulatory requirements applicable to dietary supplements and similar products, and trade policy risks including tariffs on the importation of overseas-manufactured goods.
-------------------------	--

Adverse conditions in the US market, or changes to US tariff or trade policy, could materially impact the Company's revenue and profitability.

Competition	The Company currently has a small share of the Healthy Hydration Solutions Market in the United States and competes with other larger brands and products for retail and digital shelf space. Many of the Company's competitors are multinational corporates and other large hydration brands with significantly greater access to capital, resources and distribution channels. In addition, indirect competitors not currently operating in the Healthy Hydration Solutions Market have the financial resources and manufacturing and distribution capabilities to enter the market rapidly. Should any of the Company's current or future competitors participate more aggressively on price, product, innovation or other means, or if the Company is unable to attain its targeted level of brand and product recognition, this is likely to have a material adverse impact on the Company's future financial performance and prospects.
No contracts with customers	The Company generates its revenue from uncontracted customer relationships, using the Company's or the customer's standard terms and conditions, purchase orders and invoices. These supply arrangements, which are consistent with the typical terms of supply for participants in the FMCG industry, typically have no minimum volume requirements and can be varied or terminated by the customer on short notice (or no notice) and without penalty. The Company may be unable to maintain its uncontracted relationships on commercially viable terms, which could materially adversely affect its revenue and profitability if the Company is unable to find other sources of revenue.
Brand or reputation damage	The Company's business is dependent on its reputation with customers and consumers, and the 'Hydralyte' branding is of significant value to the business. The reputation and value associated with the Hydralyte brand and related intellectual property could be adversely affected by a number of factors, including quality issues with the Company's products, failure or delay in supplying products, disputes or litigation with third parties, employees, suppliers or customers, or adverse media coverage (including social media) or publicity about the Company's products or processes. Consumer perception of Healthy Hydration Solutions products can also be substantially influenced by scientific research or findings, national media attention and other publicity about product use. A material adverse impact to the reputation of the Company or its brands could negatively affect public perception, demand for its products, customer loyalty and reputation, and could have a material adverse impact on the Company's financial and operating performance and future prospects.

Product liability and recalls	As a retailer of products designed for human consumption, the Company could be subject to product liability claims if the use of its products is alleged to have resulted in injury. The Company engages highly reputable manufacturers with quality control policies, and takes all reasonable precautions to ensure that its products are free from contamination or defects. However, events outside of the Company's control could occur. In the event that contamination, mislabelling, misbranding or another such quality control issue occurs in respect of a Company product, this may lead to business interruption, product recalls or liabilities to customers. While the Company maintains insurance to cover these risks, any amounts recovered may not be sufficient to offset any damage to the financial condition, reputation or prospects of the Company caused by a product contamination or product liability claim, or the negative publicity surrounding the claim.
No guarantee of quotation of New Options	The Company intends to apply to ASX for official quotation of the New Options (as described in Sections 2.5 and 5.2(g)). However, quotation of the New Options is subject to ASX's quotation requirements being satisfied, including that the New Options be held by at least 50 holders each with a marketable parcel. There is no guarantee that these requirements will be satisfied. If official quotation of the New Options is not granted, the New Options will be issued as unlisted securities and will not be tradeable on ASX. Even if quotation is granted, no assurance can be given that there will be, or will continue to be, an active or liquid market for the New Options, or that the trading price of the New Options will reflect the issue price, the exercise price or the value of the attaching Shares. The trading price of any quoted New Options may fall as well as rise. Nothing in this Prospectus is to be construed as stating or implying that the New Options will be quoted (listed) at any particular time, or at all.
Thin liquidity	Trading in the Company's Shares on ASX has historically been characterised by low trading volumes and limited depth of market. Thin liquidity may make it difficult for Shareholders to buy or sell Shares at or near the prevailing market price, or at all. Low liquidity can also increase the volatility of the Share price, as relatively small buy or sell orders may have a disproportionate impact on the quoted price. There is no assurance that an active or liquid market for the Shares will develop or be sustained following completion of the Offer. Shareholders who wish to sell their Shares may be unable to do so at an acceptable price, or at all, within a reasonable timeframe.
Dilutive capital raising	The Company has a history of raising capital through the issue of equity securities, including placements and rights issues, which has resulted in dilution of existing Shareholders' interests. Given the Company's current financial position and the likelihood of ongoing capital requirements,

further equity raisings may be necessary in the future to fund the Company's operations and growth. Any such future equity raisings are likely to be dilutive to Shareholders who do not participate, and may be undertaken at prices below the prevailing market price. There is no guarantee that future capital raisings will be available on terms favourable to the Company or existing Shareholders. The cumulative effect of successive dilutive capital raisings may materially reduce the proportional interest of Shareholders who do not participate.

In addition, under the Lead Manager mandate described in Section 7.7, the Company has agreed to issue 1 Broker Option to Harbour City Corporate (and/or its nominees) for every 5 New Shares issued under the Offer, on the same terms as the New Options. If the Offer is fully subscribed, up to 71,731,798 Broker Options will be issuable to the Lead Manager. If Shareholder approval for the issue of the Broker Options is obtained and the Broker Options are subsequently exercised, Shareholders who do not acquire additional Shares will experience further dilution of their proportional interest in the Company.

If Shareholder approval for the issue of the Broker Options is not obtained, the Company must issue the Broker Options under its available ASX Listing Rule 7.1 placement capacity by the deadline specified in the Lead Manager mandate. To the extent the Company has insufficient Listing Rule 7.1 capacity, or otherwise fails to issue all of the Broker Options to which the Lead Manager is entitled by that deadline, the Lead Manager may elect to call a cash settlement amount from the Company. That amount is calculated by reference to the Black-Scholes value of any unissued Broker Options at the relevant deadline and would be payable as a debt. Depending on market conditions at the relevant time, the cash settlement amount could be material and would reduce the Company's available cash resources, which could in turn require the Company to raise additional capital or defer or scale back planned expenditure.

Cost of listing	The Company incurs significant ongoing costs associated with maintaining its listing on ASX, including listing fees, compliance and regulatory costs, share registry fees, legal and audit fees, and the costs of preparing and lodging continuous disclosure documents, annual reports and other regulatory filings. These costs are fixed or semi-fixed in nature and represent a material proportion of the Company's overhead, particularly given the Company's current scale of operations and revenue. There is no assurance that the benefits of maintaining the ASX listing, including access to equity capital markets and the provision of a public trading market for Shares, will continue to outweigh the costs of doing so.
-----------------	---

Wholesale and retail channels	The Company generates revenue through wholesale distribution to third-party retailers and through its own online retail platform. The Company's wholesale business is dependent on maintaining relationships with retailers and distributors. The Company's online retail business is subject to risks associated with e-commerce, including technology failures, cybersecurity threats, changes in consumer online purchasing behaviour, and competition from established online retailers. Changes in these channels could materially affect the Company's business.
Key Personnel Risk	The Company relies on the services of certain key management personnel. The loss of any key personnel could have a materially adverse effect on the Company's business and results of operations. The Company may not be able to attract and retain suitable replacements on reasonable terms, or at all.
Additional Capital Requirements	The Company may need to raise additional capital in the future to fund its commercial activities. There is no guarantee that additional funding will be available on acceptable terms, or at all. If the Company is unable to raise sufficient capital, it may need to curtail or cease its planned activities.
IT systems, cybersecurity and data protection	The Company operates its own websites for direct purchases from and distribution to customers. The Company's websites, databases, IT, warehouse systems and management systems, and those of its key online sales channels and suppliers, are critically important to its success in attracting and retaining customers and maximising sales conversions. The Company's performance could be adversely affected by a system failure that causes disruption to its websites or the websites of its key online channels or suppliers. Despite the Company's best efforts to ensure the safe collection, storage and protection of customer data, there is a risk that a data breach may occur, or a third party may gain access to the confidential information of the Company's customers or its internal systems. This could result in a breach of law, a breach of customer agreements, significant media attention and damage to the Company's reputation and brand, and may have a material adverse effect on the Company's financial and operational performance.
Failure to execute growth plans	The Company intends to continue to grow its business, including through increased sales of its current products and the introduction of new products. There is a risk that the Company is unable to increase sales of its existing product range for a range of reasons, including loss of customers, competition, changes in consumer preferences, product safety issues and ineffective marketing campaigns. There is also a risk that the Company's new products may be unsuccessful because they are not supported by sufficient market interest and therefore fail to sell in the targeted volumes. If the Company fails to grow the sales of its existing

products and does not introduce successful new products, it will not meet its growth plans and its future financial performance and prospects will be diminished.

6.3 Industry specific risks

Risk Category	Risk Description
Reliance on third party supply chain and risk of increased costs	The Company relies on its supply chain to manufacture and distribute its products. The Company may experience disruptions and/or cost increases to its supply chain, including as a result of input cost inflation, tariffs, war, labour shortages, natural disasters or disruptions to shipping routes. Similar factors could also affect the distribution of the Company's products, which may lead to increased costs, loss of margin or an inability to procure sufficient quantities of manufactured goods in a timely fashion to meet demand.
Reliance on sales channels such as retailers and online distribution partners	The Company distributes a significant number of its products to end consumers through various sales channels, in particular online via Amazon's Marketplace. The Company depends on continued access to its sales channels in order to connect with its customers. There can be no guarantee that the Company's relationships with key channel partners will continue, or, if they do continue, that they will operate on the same terms and, in respect of retailers, that they will purchase the same, similar or greater quantities of the Company's products as they have historically.
Intellectual property risks	The Company regards its brands, trademarks, domain names, trade secrets, propriety information and similar intellectual property (IP) as important to its success. Due to the nature of the Company's products, the breakdown of active ingredients and product recipes remains broadly consistent across all competitor products and is generally clearly signposted on a product's packaging. In addition, The Company's product formulation is built on the WHO formulation for optimal absorption, which is publicly known information. Accordingly, there is limited scope for products to obtain IP protection for product formulations. The Company's IP is at risk of unauthorised use or disclosure. While the Company holds registered trade marks for the Hydralyte brand in various jurisdictions, much of its other IP is not protected (or capable of being protected) through other forms of registered intellectual property rights

(such as patent or design registrations). To enforce its IP rights, the Company may have to commence expensive and time-consuming legal proceedings against third parties who infringe its rights.

6.4 General risks

Risk Category	Risk Description
Share Market Conditions	The market price of the Company's Shares may fluctuate due to various factors, including general market conditions, investor sentiment, interest rate movements, and the operating performance of other listed companies. There can be no assurance that the Shares will trade at or above the Issue Price following completion of the Offer.
Economic Risk	Changes in the general economic climate in which the Company operates may adversely affect the financial performance of the Company. Factors that may contribute to that general economic climate include the level of interest rates, the rate of inflation, government fiscal and monetary policies, changes in government policy, and global geopolitical events.
Taxation	Any changes in tax law, or in the interpretation or administration of tax law by the relevant authorities, may adversely affect the after-tax returns of Shareholders. The tax treatment of an investment in the Company is subject to change.
Foreign Exchange Risk	A significant portion of the Company's expenditure is denominated in currencies other than Australian dollars, particularly US dollars. Movements in exchange rates may adversely affect the Company's operating costs and financial results.
Force Majeure	Events may occur within or outside Australia that could impact upon the global economy, the operations of the Company, and the price of the Company's Shares. These events include but are not limited to acts of terrorism, outbreaks of disease or pandemics, international hostilities, natural disasters, and other events beyond the control of the Company.
Legislative and Regulatory Changes	Changes to any legislation or government policy that affect the Company's operations, including taxation laws, environmental regulations, and corporate governance requirements, may adversely impact the Company's financial performance.

Insurance Risk	The Company maintains insurance within ranges of coverage it believes to be consistent with industry practice. However, no assurance can be given that the Company will be able to obtain or maintain such insurance coverage at reasonable rates or that any coverage will be adequate and available to cover all claims.
Litigation Risk	The Company may be subject to litigation, claims, and disputes in the ordinary course of business, including contractual disputes, intellectual property claims, employment disputes, and regulatory proceedings. Any such litigation could result in substantial costs and diversion of management attention and resources.

6.5 Investor acknowledgement of speculative nature

The above risk factors should not be taken as an exhaustive list of the risks that prospective investors face in making an investment in the Company. There may be additional risks and uncertainties not presently known to the Company, or that the Company currently considers immaterial, which may also have an adverse effect on the Company's business and results of operations.

Investment in the Company is speculative and involves a degree of risk. Prospective investors should consult their professional advisers, including their legal, financial and taxation advisers, before making an investment decision.

7. ADDITIONAL INFORMATION

7.1 Continuous disclosure obligations

As set out in the Important Notes section of this Prospectus, the Company is a disclosing entity for the purposes of section 713 of the Corporations Act. Accordingly, information that is already in the public domain has not been reported in this Prospectus other than that which is considered necessary to make this Prospectus complete. As at the date of this Prospectus, the Directors confirm that there is no information that has been excluded from a continuous disclosure notice given to ASX in reliance on ASX Listing Rule 3.1A that investors and their professional advisers would reasonably require, for the purposes of making an informed assessment of:

- (a) the assets and liabilities, financial position and performance, profits and losses and prospects of the Company; or
- (b) the rights and liabilities attaching to the New Securities offered under this Prospectus.

Accordingly, there is no information required to be disclosed under section 713(5) of the Corporations Act.

The Company, as a disclosing entity under the Corporations Act states that:

- (a) it is subject to regular reporting and disclosure obligations;
- (b) copies of documents lodged with the ASIC in relation to the Company (not being documents referred to in section 1274(2)(a) of the Corporations Act) may be obtained from, or inspected at, the offices of the ASIC; and
- (c) it will provide a copy of each of the following documents, free of charge, to any person on request between the date of issue of this Prospectus and the Closing Date:
 - (i) the annual financial report most recently lodged by the Company with the ASIC;
 - (ii) any half-year financial report lodged by the Company with the ASIC after the lodgement of the annual financial report referred to in (i) and before the lodgement of this Prospectus with the ASIC; and
 - (iii) any continuous disclosure documents given by the Company to ASX in accordance with the ASX Listing Rules as referred to in section 674(1) of the Corporations Act after the lodgement of the annual financial report referred to in (i) and before the lodgement of this Prospectus with the ASIC.

Copies of all documents lodged with the ASIC in relation to the Company can be inspected at the registered office of the Company during normal office hours.

Details of documents lodged by the Company with ASX since the date of lodgement of the Company's latest annual financial report and before the lodgment of this Prospectus with the ASIC are set out in the table below.

Date	Description of ASX Announcement
29 April 2026	Notice of Annual General Meeting/Proxy Form

Date	Description of ASX Announcement
29 April 2026	Letter to shareholders regarding Annual General Meeting
30 April 2026	Q1 FY26 Quarterly Report and Appendix 4C
1 May 2026	Suspension from Quotation
1 May 2026	Relodgement of FY25 Annual Report
4 May 2026	Reinstatement to Quotation
15 May 2026	Change in substantial holding
18 May 2026	Ceasing to be a substantial holder
27 May 2026	Notice of initial substantial holder
29 May 2026	2026 AGM CEO Presentation
29 May 2026	Results of 2026 Annual General Meeting
15 June 2026	Capital raising, board renewal and management changes
17 June 2026	Appendix 3B — Proposed issue of securities (Placement)
23 June 2026	Completion of Share Issue and Cleansing Statement
23 June 2026	Appendix 2A — Application for quotation of securities
25 June 2026	Notice of initial substantial holder (Mount Street Investments)
25 June 2026	Change in substantial holding
25 June 2026	Change in substantial holding
26 June 2026	Notice of initial substantial holder (Valleyrose)
1 July 2026	Initial Director's Interest Notices (G Karafotias and N Katiforis)

Date	Description of ASX Announcement
1 July 2026	Final Director's Interest Notices (A Karafili and J Constable)
1 July 2026	Change of Director's Interest Notice (N Berry)
31 July 2026	Q2 FY26 Quarterly Activities Report and Appendix 4C
31 August 2026	Appendix 4D and FY26 Half Year Financial Report
2 September 2026	Notice of Extraordinary General Meeting / Proxy Form
2 September 2026	Letter to Shareholders regarding EGM
29 September 2026	July and August 2026 Trading Update
8 October 2026	Results of Extraordinary General Meeting

ASX maintains files containing publicly available information for all listed companies. The Company's file is available for inspection at ASX during normal office hours.

The announcements are also available through the Company's website.

7.2 Market price of Shares

The Company is a disclosing entity for the purposes of the Corporations Act and its Shares are enhanced disclosure securities quoted on ASX.

The highest, lowest and last market sale prices of the Shares on ASX during the three months immediately preceding the date of lodgement of this Prospectus with the ASIC and the respective dates of those sales were:

	(\$)	Date
Highest	0.005	23 June 2026
Lowest	0.003	27 August 2026
Last	0.003	22 October 2026

7.3 Substantial Shareholders

Those Shareholders holding 5% or more of the Shares on issue at the date of this Prospectus are set out in the table below:

Shareholder	Existing Shareholding (as at the date of this Prospectus) (1)	% (2)
PURE Asset Management Pty Ltd <The Pure Income and Growth Fund> (3)	73,142,547	13.8%
Constable Group	60,986,468	11.4%
Mount Street Investments Pty Ltd <The M J Blake S/F A/C>	48,000,000	8.9%
Valleyrose Pty Ltd <Terpu Super Fund A/C>	43,750,000	8.1%
Woobinda Nominees Pty Ltd <The Woobinda Family A/C>	29,435,241	7.7%
Longhorn Capital Pty Ltd	33,492,749	6.2%
One Funds Management Ltd ATF Saville Capital Emerging Companies Fund	20,000,000	5.2%

Notes:

(1) As disclosed in the last notice lodged with the ASX by the substantial shareholder.

(2) The percentage set out in the notice lodged with the ASX is based on the total issue capital of the Company as at the date of interest.

(3) The Shares shown are held by PURE Asset Management Pty Ltd as trustee for The Pure Income and Growth Fund (**PURE**). Mr Nick Berry (Non-Executive Chairman) is deemed under section 608(3)(a) of the Corporations Act to have the same relevant interest in those Shares as PURE. PURE (and, through it, Mr Berry) also has a relevant interest in 52,442,532 Warrants of the Company. The Warrants do not carry any voting rights and are not included in the shareholding percentages set out above (which are calculated on a Shares-only basis). If PURE exercised all of its Warrants prior to the Record Date, Mr Berry's voting power would increase to approximately 21.3% of the enlarged Shares on issue immediately before the Record Date, before taking account of any take-up of Entitlements. PURE has confirmed to the Company in writing that it does not intend to exercise any of these Warrants prior to the Record Date. See also Section 4.4 (Effect on control) and Section 7.5 (Directors' interests in Securities).

In the event all Entitlements are accepted there will be no change to the substantial holders on completion of the Offer. As noted in Section 4.4 (Effect on control), PURE Asset Management Pty Ltd as trustee for The Pure Income and Growth Fund has confirmed to the Company in writing that it does not intend to exercise any of the 52,442,532 Warrants in which it (and, through it, Mr Berry) has a relevant interest prior to the Record Date, and the Company does not intend to allocate Shortfall Securities to any substantial Shareholder in a manner that would cause the acquirer's voting power to exceed 19.9%.

7.4 Interests of Directors

Other than as set out in this Prospectus, no Director or proposed director holds, or has held within the 2 years preceding lodgement of this Prospectus with the ASIC, any interest in:

- (a) the formation or promotion of the Company;
- (b) any property acquired or proposed to be acquired by the Company in connection with:
 - (i) its formation or promotion; or
 - (ii) the Offer; or
- (c) the Offer,

and no amounts have been paid or agreed to be paid and no benefits have been given or agreed to be given to a Director or proposed director:

- (d) as an inducement to become, or to qualify as, a Director; or
- (e) for services provided in connection with:
 - (i) the formation or promotion of the Company; or
 - (ii) the Offer.

7.5 Directors' interests in Securities

The relevant interest of each of the Directors in the Securities of the Company as at the date of this Prospectus, together with their respective Entitlement, is set out in the table below:

Director	Shares	Options	Warrants	Entitlement	Voting power % (2)
Nick Berry (Non-Executive Chairman)	73,142,547 (1)	Nil	52,442,532 (1)	48,761,698 New Shares 24,380,849 New Options	13.60%
George Karafotias (Non-Executive Director)	Nil	Nil	Nil	Nil	0%
Nick Katiforis (Non-Executive Director)	Nil	Nil	Nil	Nil	0%

Notes:

(1) The securities are held by PURE Asset Management Pty Ltd as trustee for The Pure Income and Growth Fund. Mr Berry is deemed to have the same relevant interests in securities that PURE Asset Management as trustee for The Pure Income and Growth Fund has by virtue of section 608(3)(a) of the Corporations Act

(2) Options and Warrants do not carry any voting rights. The percentage set out in the notice lodged with the ASX is based on the total issue capital of the Company as at the date of interest.

The Board recommends all Shareholders take up their Entitlements.

7.6 Directors' remuneration

The remuneration of an executive Director is decided by the Board, without the affected executive Director participating in that decision-making process. The total maximum remuneration of non-executive Directors is initially set by the Constitution and subsequent variation is by ordinary resolution of Shareholders in general meeting in accordance with the Constitution, the Corporations Act and the ASX Listing Rules, as applicable. The determination of non-executive Directors' remuneration within that maximum will be made by the Board having regard to the inputs and value to the Company of the respective contributions by each non-executive Director. The current amount has been set at an amount not to exceed \$350,000 per annum.

A Director may be paid fees or other amounts (i.e. non-cash performance incentives such as Options, subject to any necessary Shareholder approval) as the other Directors determine where a Director performs special duties or otherwise performs services outside the scope of the ordinary duties of a Director. In addition, Directors are also entitled to be paid reasonable travelling, hotel and other expenses incurred by them respectively in or about the performance of their duties as Directors.

The following table shows the total annual remuneration paid to Directors.

Director	FY ending 31 December 2026
Nick Berry	\$40,000
George Karafotias	\$40,000
Nick Katiforis	\$40,000

George Karafotias is an associate of Compass Group Accounting Pty Ltd, who provide financial control services to the Company for \$90,000 per annum

7.7 Lead Manager mandate

The Company has engaged Harbour City Corporate to act as lead manager in respect of the Offer and as corporate adviser for a period of 12 months. This includes marketing the Offer to Eligible Shareholders and placing the Shortfall. The key terms of the Lead Manager's mandate are as follows:

Fees

Placement Fee: 6% (plus GST) of the Gross Proceeds of the Offer (being the Rights Offer and the Shortfall Offer), payable on receipt of those funds by the Company. "Gross Proceeds" is defined by reference to the total

	securities issued multiplied by the issue price, together with any other cash proceeds funded by investors in connection with the Capital Raising. Broker Options: one option for every five New Shares issued under the Offer, to be issued to the Lead Manager (and/or its nominees) on the same terms as the New Options. Issue of the Broker Options is subject to Shareholder approval, with a fallback mechanic for issue under the Company's ASX Listing Rule 7.1 placement capacity and, failing that, a cash settlement right calculated on a Black-Scholes basis. If the Offer is fully subscribed, the Lead Manager would be entitled to approximately 71,731,798 Broker Options. Monthly Retainer: A\$6,500 (plus GST) per month for investor relations services, payable monthly in advance for 12 months from the date the Company receives Offer proceeds, subject to the Offer raising a minimum of A\$1,000,000 (before costs) in aggregate. No retainer is payable if that minimum is not achieved. Expenses: the Company will reimburse the Lead Manager's reasonable out-of-pocket expenses incurred in connection with the Engagement.
Subsequent fees on termination	No separate termination or break fee is payable on termination of the mandate. However, if the Company terminates the mandate and, during the 6 months following termination, enters into or completes a subsequent capital raising, placement or M&A transaction with an investor, counterparty or source of funds that was introduced to the Company by, or began discussions with, the Lead Manager during the term of the Engagement, the Company will be required to pay the Lead Manager the Placement Fee and issue the Broker Options (or, as applicable, the Introduction Fee) that would have been payable had the subsequent transaction been completed during the term. This does not apply where termination arises as a result of a material breach or material underperformance by the Lead Manager.
Termination Events	The mandate has a term of 12 months from the date of signing, unless terminated earlier. The Company may terminate on 14 days' notice (with a right for the Lead Manager to rectify where termination is based on dissatisfaction with service levels). The Lead Manager may terminate by written notice on the occurrence of events customary for an engagement of this nature, including: non-payment by the Company of amounts due and not remedied within 5 Business Days; the Company being unable to issue the securities or otherwise proceed with the Offer; amendment, withdrawal or revocation of any required ASX waiver or ASIC modification; ASIC (or any other person) commencing, or threatening to commence, an investigation, enquiry or proceeding in relation to the Offer; a 10% or greater fall in the S&P/ASX 200 Index over 2 consecutive Business Days; adverse Australian equity capital market or ASX trading conditions, or other material and adverse events, making it impracticable or inadvisable to proceed with the Offer; a general moratorium on commercial banking activities or a suspension of trading on specified international exchanges; any Company warranty or representation becoming materially incorrect; a

**Placement of
Shortfall
Securities**

material breach by the Company of the mandate; and the Company becoming insolvent or being placed in external administration.

The Lead Manager has been appointed to market the Rights Offer to Eligible Shareholders and to place any Shortfall Securities.

The Placement Fee of 6% (plus GST) applies to all funds raised under the Offer (comprising the Rights Offer and the Shortfall Offer), whether or not the relevant investors were introduced by the Lead Manager.

The mandate is not an underwriting of the Offer and the Lead Manager has not committed any capital or agreed to subscribe for any Shortfall Securities, although the Lead Manager (and its directors and employees) may, in their discretion, subscribe for Securities on their own account.

Exclusivity

The mandate does not contain a right of first refusal in respect of future transactions. The Lead Manager is however appointed on a sole and exclusive basis as Lead Manager during the Term of the mandate, and the Company has agreed not to appoint any third party to provide the services the Lead Manager has agreed to provide for the duration of the Term.

The Lead Manager Mandate otherwise contains provisions considered standard for an agreement of its nature (including representations, warranties and confidentiality provisions).

7.8 ASX Waivers/ASIC Relief

No waivers or relief have been sought or obtained.

7.9 Interests of experts and advisers

Certain advisers named in this Prospectus have been paid, or agreed to be paid, fees for services rendered in connection with the preparation of this Prospectus and the conduct of the Offer as disclosed in Section 7.10. No other amounts have been paid or agreed to be paid, directly or indirectly, to any of those advisers in connection with the Offer.

Other than as disclosed in this Prospectus, no expert, promoter or any other person named in this Prospectus as having performed a function in a professional, advisory or other capacity in connection with the preparation or distribution of this Prospectus holds, at the time of lodgement of this Prospectus, or held at any time during the two years before lodgement, any interest in the formation or promotion of the Company, in any property acquired or proposed to be acquired by the Company, or in the Offer.

7.10 Expenses of the Offer

The total approximate expenses of the Offer payable by the Company are:

Expense (1)	(\$) (excl. GST)
ASIC lodgement fee	\$3,457
ASX listing fee (2)	\$12,860

Lead Manager fees (3)	\$86,078
Legal fees	\$20,000
Printing and distribution	\$7,000
Miscellaneous costs	\$28,000
Total estimated costs	\$157,395

Notes:

- (1) All amounts are calculated on the basis that all Shares are issued under the Offer.
- (2) The Company intends to apply to ASX for official quotation of the New Options (see Sections 2.5 and 5.2(g)). If quotation of the New Options is not granted, the ASX listing fee reflected in the above table would be reduced accordingly and the total estimated Offer costs would be lower than shown. The Broker Options are not included in this calculation as their issue is subject to Shareholder approval; if that approval is obtained, an additional ASX quotation fee will apply.
- (3) The Lead Manager fees do not include:
 - a. the A\$6,500/month investor relations retainer (A\$78,000 excl. GST over 12 months, payable only if a minimum of A\$1,000,000 is raised, for investor relation costs generally); or
 - b. the Broker Options (~71,731,798 options at full subscription, non-cash).

7.11 Taxation

The acquisition and disposal of Securities will have tax consequences which will differ depending on the individual financial affairs of each investor. This Prospectus does not constitute tax advice and should not be relied upon as such.

All persons should seek independent professional tax advice in respect of their particular circumstances before deciding whether to apply for Securities under the Offer. The Company is not in a position to advise on the tax implications for individual investors. No stamp duty is payable by Applicants in respect of applications for New Securities under the Offer.

7.12 Consents

Each of the parties referred to below (each a **Consenting Party**), to the maximum extent permitted by law, expressly disclaims and takes no responsibility for any part of this Prospectus other than the reference to its name and a statement or report included in this Prospectus with the consent of that party as described below:

The lead manager, Harbour City Corporate, has given and has not, before lodgement of this Prospectus with ASIC, withdrawn its consent to be named in this Prospectus as lead manager in the form and context in which it is so named.

The Share Registry, Automic Pty Ltd, has given and has not, before lodgement of this Prospectus, withdrawn its consent to be named in this Prospectus as Share Registry in the form and context in which it is so named.

The Legal Advisor, KHQ Lawyers, has given and has not, before lodgement of this Prospectus, withdrawn its consent to be named in this Prospectus as Legal Advisor in the form and context in which it is so named.

7.13 Documents available for inspection

The following documents are available for inspection during normal business hours at the registered office of the Company:

- (a) this Prospectus;
- (b) the Constitution; and
- (c) the consents referred to in Section 7.12 of this Prospectus.

7.14 Legal proceedings

As at the date of this Prospectus, the Company is not involved in any legal proceedings and the Directors are not aware of any legal proceedings pending or threatened against the Company.

7.15 Governing law


This Prospectus and the contracts that arise from the acceptance of Applications are governed by the laws applicable in Victoria. Each Applicant submits to the exclusive jurisdiction of the courts of Victoria.

8. DIRECTORS' AUTHORISATION

Each of the Directors of the Company has consented to the lodgement of this Prospectus in accordance with section 720 of the Corporations Act and has not withdrawn that consent.

Dated 23 October 2026

Signed for and on behalf of The Hydration Pharmaceuticals Company Limited pursuant to a resolution of the Board of Directors passed on 22 October 2026.



Nick Berry
Non-Executive Chairman
The Hydration Pharmaceuticals Company Limited

9. GLOSSARY

TERM	MEANING
\$ or A\$	Australian dollars.
Applicant	A person who applies for New Securities.
Application Form	An Entitlement and Acceptance Form or a Shortfall Application Form, as the context requires.
ASIC	Australian Securities and Investments Commission.
ASX	ASX Limited ABN 98 008 624 691 or the securities exchange operated by it, as the context requires.
ASX Listing Rules or Listing Rules	The listing rules of ASX, as amended from time to time.
Board or Board of Directors	The board of directors of the Company.
Broker Options	The options agreed to be issued to the Lead Manager (and/or its nominees) under the Lead Manager mandate described in Section 7.7, on the basis of 1 Broker Option for every 5 New Shares issued under the Offer and on the same terms as the New Options, subject to Shareholder approval.
Business Day	A week day when trading banks are ordinarily open for business in Melbourne, Victoria.
CHESS	Clearing House Electronic Sub-register System.
Closing Date	The closing date of the Offer as set out in the Key Dates table.
Company or HPC	The Hydration Pharmaceuticals Company Limited ACN 620 385 677.
Constitution	The constitution of the Company as amended from time to time.
Corporations Act	<i>Corporations Act 2001 (Cth)</i> .
Director	A director of the Company.

TERM	MEANING
Eligible Shareholder	A Shareholder who is registered as a holder of Shares at 5.00 pm (Melbourne time) on the Record Date and has a registered address in Australia or New Zealand.
Entitlement	The entitlement of an Eligible Shareholder to subscribe for New Securities under the Rights Offer as set out in this Prospectus.
Entitlement and Acceptance Form	The personalised form accompanying this Prospectus that Eligible Shareholders must use to accept their Entitlement.
Exercise Price	\$0.006 per New Option, being the price at which each New Option may be exercised.
Expiry Date	30 June 2029, being the date on which any unexercised New Options expire.
Facility or Share Sale Facility	The share sale facility described in Section 2.10 of this Prospectus, pursuant to which Shares held by Minority Shareholders may be sold on-market by the Nominated Broker.
Facility Opt-Out Date	The date set out in the Key Dates table by which a Minority Shareholder must notify the Company that they wish to retain their Shares (or take up sufficient Entitlements to bring their holding above a Marketable Parcel) in order to be excluded from the Facility.
Facility Record Date	The date and time set out in the Key Dates table by reference to which holders of an Unmarketable Parcel are identified for the purposes of the Facility.
Harbour City Corporate or Lead Manager	Harbour City Corporate Pty Ltd ABN 99 691 790 959 (CAR No. 001318346 of Vested Equities Pty Ltd AFSL 478987).
Ineligible Shareholder	A Shareholder who is not an Eligible Shareholder.
Issue Price	\$0.004 per New Share, being the price at which New Shares are offered under this Prospectus.
Marketable Parcel	Has the meaning given in the ASX Listing Rules, being a parcel of Shares with a market value of at least A\$500 (as at the Facility Record Date, based on the closing sale price of Shares on ASX on that date).
Minority Shareholder	A Shareholder who, as at the Facility Record Date, holds an Unmarketable Parcel of Shares and has a registered address in Australia or New Zealand.

TERM	MEANING
New Options	Options offered under this Prospectus.
New Securities	The New Shares and New Options offered under this Prospectus collectively.
New Shares	The Shares offered under this Prospectus.
Nominated Broker	The broker appointed by the Company to sell Shares of Minority Shareholders under the Facility.
Offer or Rights Offer	The non-renounceable pro-rata entitlement offer of New Securities described in this Prospectus.
Offer Period	The period commencing on the Opening Date and ending on the Closing Date.
Official List	The official list of ASX.
Opening Date	The opening date of the Offer as set out in the Key Dates table.
Option	An option to acquire a Share in the Company.
Prospectus	This prospectus dated 23 October 2026, including any supplementary or replacement prospectus in relation to this document.
Prospectus Date	The date of this Prospectus.
Quotation	Quotation of the Shares on the Official List.
Record Date	28 October 2026, being the date by reference to which Eligible Shareholders are identified.
Section	A section of this Prospectus.
Securities	Shares and/or Options, as the context requires.
Share	A fully paid ordinary share in the capital of the Company.
Share Registry	Automic Pty Ltd.
Shareholder	A registered holder of a Share.
Shortfall	Those New Securities that are not subscribed for by Eligible Shareholders under the Rights Offer.

TERM	MEANING
Shortfall Application Form	The shortfall application form accompanying this Prospectus.
Shortfall Offer	The offer of Shortfall Securities as described in this Prospectus.
Shortfall Securities	Those New Securities that form the Shortfall.
Unmarketable Parcel	A parcel of Shares that is not a Marketable Parcel.
Warrants	The warrants on issue in the Company, comprising: 14,942,533 exercisable at \$0.29 or 80% of the applicable share price under a qualifying change of control transaction. Expiring 3 November 2026. 85,000,000 exercisable at \$0.02 or 80% of the applicable share price under a qualifying change of control transaction. Expiring 27 March 2028.

CORPORATE DIRECTORY

The Hydration Pharmaceuticals Company Limited

ACN 620 385 677

C/- CDPLUS CORPORATE SERVICES PTY LTD

LEVEL 13, 440 COLLINS STREET

MELBOURNE VIC 3000

ASX Code: HPC

Website: www.hydralyte.com

Directors

Nick Berry — Non-Executive Chairman

George Karafotias — Non-Executive Director

Nick Katiforis — Non-Executive Director

Lead Manager

Harbour City Corporate Pty Ltd

Suite 1401, Level 14, 56 Pitt Street

Sydney NSW 2000

Legal Advisor

KHQ Lawyers

Level 4, 600 Bourke Street

Melbourne VIC 3000

Share Registry

Automic Pty Ltd

Level 5, 126 Phillip Street

Sydney NSW 2000